Innovent Biologics マネジメント

マネジメント基準チェック /14

Innovent Biologicsの CEO はMichael Yuで、 Jan2011年に任命され、の在任期間は 14.08年です。の年間総報酬はCN¥ 36.44Mで、 7.9%給与と92.1%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の6.53%を直接所有しており、その価値はHK$ 3.54B 。経営陣と取締役会の平均在任期間はそれぞれ1年と3.5年です。

主要情報

Michael Yu

最高経営責任者

CN¥36.4m

報酬総額

CEO給与比率	7.9%
CEO在任期間	14.1yrs
CEOの所有権	6.5%
経営陣の平均在職期間	1yr
取締役会の平均在任期間	3.5yrs

経営陣の近況

Recent updates

CEO報酬分析

Innovent Biologics の収益と比較して、Michael Yu の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	n/a	n/a	-CN¥1b
Mar 31 2024	n/a	n/a	-CN¥1b
Dec 31 2023	CN¥36m	CN¥3m	-CN¥1b
Sep 30 2023	n/a	n/a	-CN¥1b
Jun 30 2023	n/a	n/a	-CN¥1b
Mar 31 2023	n/a	n/a	-CN¥2b
Dec 31 2022	CN¥33m	CN¥3m	-CN¥2b
Sep 30 2022	n/a	n/a	-CN¥2b
Jun 30 2022	n/a	n/a	-CN¥3b
Mar 31 2022	n/a	n/a	-CN¥3b
Dec 31 2021	CN¥26m	CN¥3m	-CN¥3b
Sep 30 2021	n/a	n/a	-CN¥2b
Jun 30 2021	n/a	n/a	-CN¥1b
Mar 31 2021	n/a	n/a	-CN¥1b
Dec 31 2020	CN¥105m	CN¥3m	-CN¥998m
Sep 30 2020	n/a	n/a	-CN¥1b
Jun 30 2020	n/a	n/a	-CN¥2b
Mar 31 2020	n/a	n/a	-CN¥2b
Dec 31 2019	CN¥76m	CN¥3m	-CN¥2b

報酬と市場: Michaelの総報酬 ($USD 5.03M ) は、 Hong Kong市場 ($USD 846.38K ) の同規模の企業の平均を上回っています。

報酬と収益: Michaelの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Michael Yu (60 yo)

14.1yrs

在職期間

CN¥36,444,000

報酬

Dr. De-Chao Yu, also known as Michael, Ph.D. Co-Founded Innovent Biologics, Inc. in August 2011 and has been its Chairman and Chief Executive Officer since 2011. He served as its President at Innovent Biol...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
De-Chao Yu	Co-Founder	14.1yrs	CN¥36.44m	6.53% HK$ 3.5b
Hao Xi Ede	Executive Director & Fund Managing Partner	1yr	CN¥7.10m	0.20% HK$ 107.6m
Fei You	Chief Financial Officer	1yr	データなし	データなし
Vivian Zhang	Chief People Officer	5.6yrs	データなし	0.020% HK$ 11.1m
Min Liu	Chief Commercial Officer	no data	データなし	データなし
Dongming Wang	Senior Vice President	5.1yrs	データなし	データなし
Blake Salisbury	Senior Vice President	no data	データなし	データなし
Hui Zhou	Senior Vice President	1.1yrs	データなし	データなし
Nageatte Ibrahim	Oncology Chief Medical Officer	less than a year	データなし	データなし
Samuel Suhua Zhang	Global Chief Business Officer	less than a year	データなし	データなし
Raj Dhodda	Senior Vice President	less than a year	データなし	データなし
Lei Qian	Senior Vice President	less than a year	データなし	データなし

1.0yrs

平均在職期間

53.5yo

平均年齢

経験豊富な経営陣: 1801の経営陣は経験豊富とはみなされません ( 1年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
De-Chao Yu	Co-Founder	14.1yrs	CN¥36.44m	6.53% HK$ 3.5b
Hao Xi Ede	Executive Director & Fund Managing Partner	no data	CN¥7.10m	0.20% HK$ 107.6m
Vivian Zhang	Chief People Officer	less than a year	データなし	0.020% HK$ 11.1m
Charles Leland Cooney	Member of CMC Strategic Advisory Board & Independent Non-Executive Director	9.3yrs	CN¥400.00k	0.0028% HK$ 1.5m
Lewis Lanier	Member of Scientific Advisory Board	3.5yrs	データなし	データなし
I-Yin Hsu	Independent Non-Executive Director	6.3yrs	CN¥400.00k	0.00039% HK$ 211.1k
Erwin Vanhaecke	Member of CMC Strategic Advisory Board	no data	データなし	データなし
Chiang Syin	Member of CMC Strategic Advisory Board	no data	データなし	データなし
David LaPre	Member of CMC Strategic Advisory Board	no data	データなし	データなし
Shuyun Chen	Independent Non-Executive Director	less than a year	データなし	0.00067% HK$ 362.7k
Lawrence Fong	Member of Scientific Advisory Board	3.5yrs	データなし	データなし
Carlos Garcia-Echeverria	Member of Scientific Advisory Board	3.5yrs	データなし	データなし

3.5yrs

平均在職期間

60yo

平均年齢

経験豊富なボード: 1801の取締役会は経験豊富であると考えられます ( 3.5年の平均在任期間)。

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2025/02/02 06:07
終値	2025/01/28 00:00
収益	2024/06/30
年間収益	2023/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を例とし、非米国証券については同等の規制書式と情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら

分析モデルとスノーフレーク

このレポートの作成に使用した分析モデルの詳細は、Githubページでご覧いただけます。また、レポートの使用方法に関するガイドや、Youtubeでのチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Innovent Biologics, Inc. 28 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。55

アナリスト	機関
Wai Chak Yuen	BOCI Research Ltd.
Linda Lu	BOCI Research Ltd.
Bo Li	BofA Global Research

Innovent Biologics マネジメント

マネジメント 基準チェック /14

主要情報

経営陣の近況

Co-Founder recently sold HK$81m worth of stock

Innovent Biologics, Inc. Announces Change in Composition of Board Committees

High number of new directors

Co-Founder recently sold HK$37m worth of stock

Innovent Biologics, Inc. Appoints Samuel Zhang as Global Chief Business Officer

Innovent Biologics, Inc., Annual General Meeting, Jun 21, 2024

Recent updates

Innovent Biologics, Inc. and Jiangsu Aosaikang Pharmaceutical Co. Ltd. Jointly Announce NMPA Approval of Limertinib, a Third-Generation EGFR TKI for the Treatment of Lung Cancer

Innovent Biologics, Inc. Announces National Medical Products Administration of China Approves Second New Drug Application of DOVBLERON

Innovent Biologics, Inc. announced that it has received funding from Xuhui Science and Technology Venture Capital

Innovent Biologics, Inc. Receives Approval of DOVBLERON®? (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration

Innovent Presents Updated Data from Innovative Anti-CLDN18.2 Adc (Ibi343) Phase 1 Study in Patients with Advanced Pancreatic Cancer at the Esmo Asia Congress 2024

Innovent Biologics, Inc. Announces First-Time Inclusion of SINTBILO and New Indication for Olverembatinib in China's National Reimbursement Drug List

Co-Founder recently sold HK$81m worth of stock

First half 2024 earnings released: CN¥0.24 loss per share (vs CN¥0.091 loss in 1H 2023)

Innovent Biologics, Inc. Announces Acceptance of New Drug Application for Picankibart Injection by China's NMPA

Innovent Biologics, Inc. Announces Clinical Data of IBI363 (First-in-class PD-1/IL-2a-bias Bispecific Antibody Fusion Protein) Combined with Bevacizumab in Advanced Colorectal Cancer at the 2024 ESMO Congress

Forecast to breakeven in 2025

Innovent Biologics, Inc. Announces Change in Composition of Board Committees

First half 2024 earnings released: CN¥0.24 loss per share (vs CN¥0.091 loss in 1H 2023)

Innovent Biologics, Inc. Announces the Approval of Dupert® (Fulzerasib) by the National Medical Products Administration of China

The National Medical Products Administration Approves Centre for Drug Evaluation of the National Medical Products Administration of China's First KRAS G12C Inhibitor Dupert

Innovent Biologics, Inc. to Report First Half, 2024 Results on Aug 28, 2024

Innovent Biologics, Inc. and Sanegene Bio USA Inc. Announces First Participant Dosed in a Phase 1 Clinical Trial of IBI3016 (AGT siRNA)

the National Medical Products Administration of China Accepts the New Drug Application of Mazdutide of Innovent Biologics, Inc

Innovent Biologics, Inc. Presents the Results of the First Phase 3 Study of Mazdutide for Weight Management at the ADA's 84th Scientific Sessions

High number of new directors

Innovent Biologics, Inc. Announces Picankibart (IBI112) Achieved Primary Endpoints in A Phase 3 Clinical Trial in Treating Moderate to Severe Plaque Psoriasis, and Plans to the NDA to the NMPA

Innovent Biologics Announces National Medical Products Administration of China Accepts the New Drug Application for IBI311

Co-Founder recently sold HK$37m worth of stock

Innovent Receives NMPA Breakthrough Therapy Designation for IBI343(Anti-Claudin18.2 ADC) as Monotherapy for Advanced Gastric Cancer

Full year 2023 earnings released: CN¥0.66 loss per share (vs CN¥1.46 loss in FY 2022)

Innovent Biologics, Inc. Appoints Samuel Zhang as Global Chief Business Officer

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status

Innovent Biologics, Inc. Announces the National Medical Products Administration Accepts the New Drug Application

Innovent Biologics, Inc., Annual General Meeting, Jun 21, 2024

Full year 2023 earnings released: CN¥0.66 loss per share (vs CN¥1.46 loss in FY 2022)

Innovent Biologics, Inc. Releases the Results of Two Clinical Studies of Ibi311 (An Anti-IGF-1R Monoclonal Antibody) in Oral Presentations At the Asia-Pacific Academy of Ophthalmology Congress and International Congress of Endocrinology 2024

Anheart Therapeutics and Innovent Announces China’s NMPA Accepted Second New Drug Application for Taletrectinib for First-Line Treatment of Ros1-Positive Lung Cancer

Now 25% undervalued after recent price drop

Innovent Biologics, Inc. to Report Fiscal Year 2023 Results on Mar 20, 2024

Innovent Biologics, Inc. Announces the Phase 3 Clinical Study of Ibi311 Met the Primary Endpoint in Treating Thyroid Eye Disease

Innovent Biologics, Inc. Announces Appointment of Shun Lu as Independent Non-Executive Director and A Member of the Strategy Committee

Innovent Biologics, Inc.'s First New Drug Application of Mazdutide for Chronic Weight Management Has Been Accepted by the NMPA of China

Innovent Biologics, Inc. Announces Chief Financial Officer Changes

Innovent Biologics, Inc. Announces the First Phase 3 Clinical Trial of Mazdutide Inchinese Adults with Overweight or Obesity Metthe Primary and All Key Secondary Endpoints

China’S National Medical Products Administration Grants Anheart Therapeutics and Innovent Biologics, Inc. Taletrectinib (Ros1 Inhibitor) Priority Review Designation for the New Drug Application (Nda) of Taletrectinib

Innovent Biologics, Inc. Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Overweight or Obesity in Nature Communications

Innovent Biologics, Inc. Announces the Phase 3 Orient-16 Study Results Published in JAMA Evaluating Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma

Innovent Biologics, Inc. Announces the National Medical Products Administration of China Accepts and Grants Priority Review Designation to the New Drug Application for IBI351

Innovent Biologics, Inc. Announces Acceptance of New Drug Application from National Medical Products Administration for Taletrectinib

Innovent Biologics, Inc Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Type 2 Diabetes in Diabetes Care

The National Medical Products Administration Approves Olverembatinib for the Treatment of Cml-Cp Patients

Now 20% undervalued

Innovent Biologics, Inc. Announces Robust Weight Loss Efficacy, Multiple Metabolic Benefits and Favorable Safety Profile of Higher Dose 9 mg Mazdutide (IBI362) after 48-week Treatment in Phase 2 Study for Obesity

Innovent Biologics, Inc. Announces Update on the New Drug Application for Parsaclisib (PI3Kd Inhibitor)

Innovent Biologics, Inc. has completed a Follow-on Equity Offering in the amount of HKD 2.35688 billion.

Innovent Biologics, Inc. has completed a Follow-on Equity Offering in the amount of HKD 2.35688 billion.

New minor risk - Shareholder dilution

First half 2023 earnings released: CN¥0.091 loss per share (vs CN¥0.65 loss in 1H 2022)

National Medical Products Administration Approves New Drug Application for Innovent Biologics, Inc.'s Sintbilo

Innovent Biologics, Inc. to Report Q2, 2023 Results on Aug 23, 2023

IASO Bio and Innovent Announce the NMPA Approval of the New Drug Application for Equecabtagene Autoleucel, the World's First Fully-human BCMA CAR-T Therapy, for the Treatment of Relapsed and/or Refractory Multiple Myeloma

Innovent Biologics, Inc. Announces Phase 1 Clinical Data of IBI322 (CD47/PD-L1 Bispecific Antibody) in the Treatment of Anti-PD-(L)1-Resistant Classic Hodgkin Lymphoma Patients at the EHA 2023 Annual Meeting

Innovent Presents Phase 1 Clinical Data of IBI351 as Monotherapy for Metastatic Colorectal Cancer at the 2023 ASCO Annual Meeting

Innovent Updates Phase 1B Data of IbI939 (Anti-Tigit Monoclonal Antibody) Combined with Sintilimab in Previously Untreated PD-L1-Selected NSCLC

Innovent Announces the Second Breakthrough Therapy Designation by NMPA for Olverembatinib for the Treatment of Patients with SDH-Deficient GIST

Innovent Biologics, Inc. Announces Phase 2 Clinical Study of Higher dose 9 mg Mazdutide (IBI362) in Chinese Adults with Obesity Achieved the 24-Week Primary Endpoint

Innovent Biologics, Inc. Announces National Medical Products Administration Approves TYVYT (Sintilimab Injection) in Combination with Bevacizumab and Chemotherapy in Patients with EGFR-Mutated Non-Squamous Nsclc Who Progressed After EGFR-TKI Therapy

Full year 2022 earnings released: CN¥1.46 loss per share (vs CN¥2.16 loss in FY 2021)

Innovent Announces First Patient Dosed in a Phase 3 Clinical Trial (CLEAR) of Picankibart (Anti-IL23p19 Monoclonal Antibody) in Patients with Moderate-to-Severe Plaque Psoriasis

Innovent Biologics, Inc. Announces First Participant Dosed in Phase 2 Study of IBI311 (Anti-IGF-1R Monoclonal Antibody) in Patients with Thyroid Associated Ophthalmopathy

Innovent Announces Inclusion in the China National Reimbursement Drug List (NRDL) of TYVYT in Two New Indications, Olverembatinib for the First Listing, BYVASDA, HALPRYZA and SULINNO in Multiple New Indications

Innovent Biologics, Inc. Announces First Participant Dosed in A Phase 3 Clinical Study (Dreams-1) of Mazdutide (IBI362) in Chinese Patients with Type 2 Diabetes

Innovent Biologics, Inc. Announces the National Medical Products Administration in China Has Accepted and Granted Priority Review Designation to the New Drug Application for Parsaclisib

Forecast to breakeven in 2025

マネジメント基準チェック /14